Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Stock data | 2024 | Change |
---|---|---|
Price | $0.23 | N/A |
Market Cap | $5.31M | N/A |
Shares Outstanding | 23.08M | N/A |
Employees | 14.00 | N/A |